On May 26, 2022, BD (Becton, Dickinson) announced a new high-throughput molecular diagnostic combination test for SARS-CoV-2 and Influenza A/B, the second test available for the BD COR PX/MX System to have been CE marked to the IVD directive 98/79/EC.

The BD SARS-CoV-2/Flu assay for the BD COR System is an automated multiplexed real-time RT-PCR test to detect and differentiate SARS-CoV-2 and influenza A, and/or influenza B from a single nasal sample from patients who are showing signs of respiratory viral infection, as well as those who are asymptomatic.